ClinicoEconomics and Outcomes Research (Sep 2020)

OUD Care Service Improvement with Prolonged-release Buprenorphine in Prisons: Cost Estimation Analysis

  • Wright N,
  • Hard J,
  • Fearns C,
  • Gilman M,
  • Littlewood R,
  • Clegg R,
  • Parimelalagan L,
  • Alam F

Journal volume & issue
Vol. Volume 12
pp. 499 – 504

Abstract

Read online

Nat Wright,1 Jake Hard,2 Colin Fearns,3 Mark Gilman,4 Richard Littlewood,5 Rachael Clegg,6 Luxman Parimelalagan,3 Farrukh Alam7 1Spectrum Community Health CIC, Wakefield, UK; 2Royal College of General Practitioners, London, UK; 3Delphi Medical, Lancashire, UK; 4Discovering Health, Manchester, UK; 5applied strategic, London, UK; 6Change Grow Live, Brighton, UK; 7Central & North West London NHS Foundation Trust, London, UKCorrespondence: Nat WrightSpectrum Community Health CIC, One Navigation Walk, Hebble Wharf, Wakefield WF1 5RH, UKEmail [email protected]: In prisons in England, integrated treatment for opioid use disorder (OUD) is accessible and effective, commonly based on daily supervised consumption of methadone. Treatment limitations (inadequate dosing, nonengagement with care, stigma, diversion and bullying) are noted. Flexible dose, injectable prolonged-release buprenorphine (PRB) which removes the need for daily dispensing and supervision is suggested for prisoner care. This work aimed to predict the difference in costs of current standard of care vs partial introduction of PRB.Methods: A predictive model of compared costs for the provision of OUD care in the prison setting in England evaluated current standard of care (all receive methadone) with a future situation of 30% of prisoners electing to use a monthly dose of PRB. Evidence describing costs to deliver OUD care for 150 prisoners (pharmacotherapy, direct service, indirect health care, indirect security costs) were collected, including assumptions describing how care would be delivered. Evidence sources include national data sources, scientific literature and from experience in the prison health care setting.Results: For a representative standard prison population requiring OUD care of 150 prisoners in England PRB introduction is associated with a predicted reduction in direct and indirect costs of OUD care. Annual OUD care costs for current standard of care were £ 0.6M; with 30% PRB costs reduced by £ 8665, more than 3000 hours of staff time is saved. Sensitivity analyses showed greater adoption of PRB resulted in further cost reduction.Conclusion: PRB can address limitations of OUD care in prisons and improve outcomes. Introduction does not increase cost of care in this predictive analysis. PRB may lead the transformation of prisoner OUD care.Keywords: opioid use disorder, pharmacotherapy, prolonged-release buprenorphine, prisoners

Keywords